Avecho Biotechnology Ltd - フェーズIII中間解析は2026年6月に予定

197 Views10 Mar 2026 06:00

Issuer-paid

SUMMARY

Avecho Biotechnology Limited (ASX:AVE) is an Australian biotech company focused on enhancing drug absorption through its proprietary TPM (Tocopheryl Phosphate Mixture).
AVE is currently focusing its efforts on a CBD (Cannabidiol) soft-gel capsule for treating insomnia and is presently undergoing a pivotal Phase III clinical trial of the drug with the potential to be the first over-the-counter (OTC) CBD sleep aid approved by Australia’s Therapeutic Goods Administration (TGA).
On 2 March 2026, AVE announced that it had completed the much-anticipated recruitment of ~210 patients required for interim analysis of the Phase III trial with results anticipated in June 2026.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream